Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 9, Iss. 1, 2009-03 ,pp. : 14-28

Bentham Science Publishers

Access to resources Recommend Favorite

Interferon-Beta in the Treatment of Multiple Sclerosis: Do Clinical Data Support the Existence of a Ceiling Effect?

By Clanet M.  

Clinical Drug Investigation, Vol. 21, Iss. 4, 2001-04 ,pp. : 307-318

Adis International

Access to resources Recommend Favorite

Treating Relapsing Multiple Sclerosis with Subcutaneous versus Intramuscular Interferon-Beta-1a: Modelling the Clinical and Economic Implications

By Guo Shien   Bozkaya Duygu  

PharmacoEconomics, Vol. 27, Iss. 1, 2009-01 ,pp. : 39-53

Adis International

Access to resources Recommend Favorite

A Population Approach to Characterize Interferon Beta‐1b Effect on Contrast Enhancing Lesions in Patients With Relapsing Remitting Multiple Sclerosis

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 5, 2015-05 ,pp. : 295-304

John Wiley & Sons Inc

Access to resources Recommend Favorite

Interferon-: Sclerosing skin disorders in patients with multiple sclerosis?: 3 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1234, 2009-01 ,pp. : 24-24

Adis International

Access to resources Recommend Favorite